Capital World Investors’s KalVista Pharmaceuticals KALV Stock Holding History

Capital World Investors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.5M	Hold	2,808,583	–	–	0.01%	443
2025 Q4	$45.4M	Sell	2,808,583 -369,004	-12%	-$4.89M	0.01%	425
2025 Q3	$38.7M	Hold	3,177,587	–	–	0.01%	441
2025 Q2	$35.9M	Hold	3,177,587	–	–	0.01%	443
2025 Q1	$36.7M	Sell	3,177,587 -196,477	-6%	-$2.01M	0.01%	427
2024 Q4	$28.6M	Hold	3,374,064	–	–	﹤0.01%	444
2024 Q3	$39.1M	Buy	3,374,064 +146,444	+5%	+$1.84M	0.01%	416
2024 Q2	$38M	Buy	3,227,620 +1,763,014	+120%	+$20.6M	0.01%	405
2024 Q1	$17.4M	Buy	+1,464,606	New	+$19.5M	﹤0.01%	463

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Capital World Investors's KALV Position: Q1 2026 in Review

Capital World Investors held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 2,808,583 shares worth $56.5M. The position accounts for 0.01% of the portfolio, ranked #443.

Capital World Investors first reported a position in KALV in Q1 2024 and has held it in 9 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Capital World Investors held 2,808,583 shares of KalVista Pharmaceuticals worth $56.5M as of Q1 2026.
Capital World Investors left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
KalVista Pharmaceuticals made up 0.01% of Capital World Investors's portfolio in Q1 2026, its #443 holding.
Capital World Investors first reported a position in KalVista Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Capital World Investors's 13F filing for Q1 2026, filed 13 May 2026.